医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Solasia Pharma and Meiji Seika Pharma Announce License and Distribution Agreement for episil® (oral liquid)

2016年12月05日 PM03:00
このエントリーをはてなブックマークに追加


 

TOKYO

Solasia Pharma K.K. (Headquarters: Tokyo, Japan, President: Yoshihiro Arai, hereinafter “Solasia”) announced today that Solasia and Meiji Seika Pharma Co. Ltd., (Headquarters: Tokyo, Japan, President: Daikichiro Kobayashi, hereinafter “Meiji”) have entered into a license and distribution agreement for the commercialization of episil® (SP-03) in Japan.

Under the terms of this agreement, Solasia will target to obtain approval for episil® for local treatment of pain associated with oral mucositis (OM) in Japan and thereafter Meiji will commercialize, distribute and promote episil®. In consideration of the license granted to Meiji, Solasia will receive upfront and milestone payments, as well as tiered royalties.

Solasia has obtained an exclusive license to develop and commercialize episil® in Japan and China from Camurus AB (“Camurus”) (STO: CAMX). In 2016, Solasia filed for New Medical Device Application for episil® (SP-03) in Japan and China.

episil® oral liquid represents a unique and innovative concept for local treatment of pain associated with oral mucositis (OM). Having been developed using the award-winning* Camurus proprietary technology FluidCrystal®, episil® is administered as lipid-based liquid that spreads on the intraoral mucosal surfaces and transforms to strongly bioadhesive film, which physically protects the sensitized and sore mucosa of the oral cavity. episil® has clinically demonstrated to rapidly (within minutes) and effectively reduce oral pain for up to 8 hours. episil® oral liquid is the only product for OM that is supplied as a ready-to-use, pocket-sized device helping patients maintain their quality of life while undergoing cancer therapy. episil® was first launched in Europe in 2009 and is today commercially available in a number of countries, including the U.S. where it was launched by key global pharmaceutical players. episil® oral liquid is a medical device class 1 in Europe and a 510(k) registered medical device in the U.S.

*FluidCrystal® was awarded the “Best innovation in formulation” prize at the CPhI Worldwide in 2013

About Meiji Seika Pharma Co., Ltd.: – Ethical Pharmaceuticals Business:

As a “Specialty and Generic Pharmaceuticals Company”, Meiji runs its pharmaceutical business in the three main fields, infectious disease and central nervous system disorders, and generic drugs. Meiji strives to respond to diversified medical needs and contributes to the well-being of people worldwide. For details, please visit its corporate website:

http://www.meiji.com/global/about-us/corporate-profile/meiji-seika-pharma/

About Solasia:

Solasia was formed in November 2006 to address unmet needs for important new Western oncology therapies and supportive care products throughout Asia. The company’s mission is to expedite patient access to unique oncology therapies through aggressive development and specialized commercialization throughout Japan, China and other Asian countries. To date, Solasia has raised approximately $80 million in venture financing. Additional information is available at http://www.solasia.co.jp/en/

View source version on businesswire.com: http://www.businesswire.com/news/home/20161204005067/en/

CONTACT

For Solasia Pharma K.K.
Koji Shinozaki, +81-3-6721-8330
Business
Development
kshinozaki@solasia.co.jp
or
Annes
Associates
Shari Annes, +1 650-888-0902
sannes@annesassociates.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc